RU2008136080A - Антитела к секретируемому frizzled-родственному белку-4 (sfrp-4) - Google Patents

Антитела к секретируемому frizzled-родственному белку-4 (sfrp-4) Download PDF

Info

Publication number
RU2008136080A
RU2008136080A RU2008136080/13A RU2008136080A RU2008136080A RU 2008136080 A RU2008136080 A RU 2008136080A RU 2008136080/13 A RU2008136080/13 A RU 2008136080/13A RU 2008136080 A RU2008136080 A RU 2008136080A RU 2008136080 A RU2008136080 A RU 2008136080A
Authority
RU
Russia
Prior art keywords
polypeptide
antibody
seq
cancer
secreted frizzled
Prior art date
Application number
RU2008136080/13A
Other languages
English (en)
Russian (ru)
Inventor
Аннетте ЦААР (DE)
Аннетте ЦААР
Райнер ХИЛЛЕНБРАНД (DE)
Райнер Хилленбранд
Алессандра ВИТАЛИТИ (CH)
Алессандра ВИТАЛИТИ
Original Assignee
Новартис АГ (CH)
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис АГ (CH), Новартис Аг filed Critical Новартис АГ (CH)
Publication of RU2008136080A publication Critical patent/RU2008136080A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
RU2008136080/13A 2006-02-09 2007-02-08 Антитела к секретируемому frizzled-родственному белку-4 (sfrp-4) RU2008136080A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77165106P 2006-02-09 2006-02-09
US60/771,651 2006-02-09

Publications (1)

Publication Number Publication Date
RU2008136080A true RU2008136080A (ru) 2010-03-20

Family

ID=38335655

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008136080/13A RU2008136080A (ru) 2006-02-09 2007-02-08 Антитела к секретируемому frizzled-родственному белку-4 (sfrp-4)

Country Status (9)

Country Link
EP (1) EP1991582A2 (fr)
JP (1) JP2009526020A (fr)
KR (1) KR20080113196A (fr)
CN (1) CN101370826A (fr)
AU (1) AU2007213655A1 (fr)
BR (1) BRPI0710442A2 (fr)
CA (1) CA2637775A1 (fr)
RU (1) RU2008136080A (fr)
WO (1) WO2007090872A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
CN101506236B (zh) 2005-11-30 2012-12-12 雅培制药有限公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (fr) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Procédé pour le traitement des amyloses
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
CN102965448A (zh) * 2012-12-12 2013-03-13 芮屈生物技术（上海）有限公司 糖尿病病理演变前期SFRP4基因的mRNA水平原位杂交检测试剂盒及检测方法和应用
WO2015172201A1 (fr) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarqueur du cancer gastrique
CN117337394A (zh) 2021-05-17 2024-01-02 豪夫迈·罗氏有限公司 sFRP4作为血液生物标志物用于子宫腺肌病的非侵入性诊断

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075280A2 (fr) * 1999-06-08 2000-12-14 Smithkline Beecham Corporation Membre de la famille frzb
EP1222933A1 (fr) * 2001-01-15 2002-07-17 Academisch Ziekenhuis Leiden h.o.d.n., Leids Universitair Medisch Centrum Génération et/ou réduction de nouveau tissu pulmonaire dans un poumon atteint, par modulation de la voie Wnt
WO2002092128A1 (fr) * 2001-05-11 2002-11-21 Genzyme Corporation Compositions et procedes permettant de reguler le phosphate de serum
EP1808694A1 (fr) * 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Procédé de diagnostic d'une maladie polykystique des reins

Also Published As

Publication number Publication date
CA2637775A1 (fr) 2007-08-16
WO2007090872A3 (fr) 2007-11-29
KR20080113196A (ko) 2008-12-29
AU2007213655A1 (en) 2007-08-16
EP1991582A2 (fr) 2008-11-19
WO2007090872A2 (fr) 2007-08-16
CN101370826A (zh) 2009-02-18
JP2009526020A (ja) 2009-07-16
BRPI0710442A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
RU2008136080A (ru) Антитела к секретируемому frizzled-родственному белку-4 (sfrp-4)
US11174309B2 (en) Anti-ANG2 antibody
RU2434882C2 (ru) Новые антитела к igf-ir и их применение
CA2621363C (fr) Methodes et compositions permettant de moduler l'activite des cellules tumorales
RU2012118643A (ru) Антитела против сиглека-15 для лечения заболевания, связанного с потерей костной массы
KR101016476B1 (ko) 섬유아세포 증식 인자-23에 대한 항체
JPWO2009008529A1 (ja) Ｔｄｐ−４３凝集物に特異的に結合する抗体
KR20100023869A (ko) 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
JPWO2009119455A1 (ja) がん細胞運動およびがん細胞浸潤抑制剤
SG177514A1 (en) New tumor marker
JP2002518001A (ja) Ｇ３ｂｐタンパク質に対するモノクローナル抗体及びその使用
JP2010046057A (ja) 癌細胞の治療感受性増強剤、癌細胞の治療感受性の判定方法、および癌細胞の治療感受性判定キット
US20210363244A1 (en) Epitope of Regulatory T Cell surface Antigen and Antibody Specifically Biding Thereto
US8975030B2 (en) Method for cancer detection
DiCara et al. Characterization and structural determination of a new anti-MET function-blocking antibody with binding epitope distinct from the ligand binding domain
US20230080534A1 (en) Semg2 antibody and use thereof
Qin et al. A fully human connective tissue growth factor blocking monoclonal antibody ameliorates experimental rheumatoid arthritis through inhibiting angiogenesis
CN111699002A (zh) 具有细胞内穿透能力的抗信号转导与转录激活因子3双特异性抗体及包含其的药学组合物
Sun et al. Isoform-selective TGF-β3 inhibition for systemic sclerosis
US20110300068A1 (en) Agent for prophylaxis or treatment of cancer
EP4219550A1 (fr) Anticorps monoclonaux contre l'eltd1 et leurs utilisations
CA2714880C (fr) Nouveau biomarqueur de tumeur
EP3144321A1 (fr) Protéine dickkopf 3 (dkk3) de mammifère comme marqueur urinaire de la fibrose rénale interstitielle/atrophie tubulaire (si/ta) et de l'insuffisance rénale progressive
JP2015196666A (ja) 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬
JP2004141161A (ja) ズブチリシン様プロプロテインコンベルターゼ・ｐａｃｅ４に対するモノクローナル抗体及びその利用

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110120